Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

tion of worldwide VELCADE sales growth. Year-to-date, we have approximately tripled our non-GAAP net income and reduced GAAP net loss by 50 percent, compared to the same period last year," (1) commented Marsha Fanucci, Chief Financial Officer, Millennium. "Our increased financial guidance now projects that VELCADE U.S. net sales will grow 20 percent in 2007 to approximately $265 million."

Third Quarter 2007 Financial Results

-- The Company achieved non-GAAP net income of $15.3 million in the third

quarter of 2007 compared to $6.4 million in the third quarter of 2006.

This significant improvement resulted from an increase in VELCADE U.S.

net sales and royalties. These improvements were partially offset by

an increase in investments to support the continued growth of VELCADE.

Key financial results for the quarter, as compared to the third quarter

of 2006, included:

-- VELCADE U.S. net sales of $70.4 million, a 32 percent increase;

-- Royalties of $41.3 million, a 23 percent increase;

-- Net investment income of $8.6 million, a 31 percent increase;

-- Non-GAAP research and development (R&D) expense of $69.5 million

(corresponding GAAP R&D expense, including stock-based compensation,

of $72.6 million); (2) and

-- Non-GAAP selling, general and administrative (SG&A) expense of $39.2

million (corresponding GAAP SG&A expense, including stock-based

compensation, of $42.9 million). (2)

Year-to-date, the Company achieved $31.3 million in non-GAAP net

income compared to $11.2 million for the same period of 2006.

-- The Company narrowed GAAP net loss to $1.7 million for the third

quarter of 2007 from $13.7 million in the third quarter of 2006. The

improvement in the Company's GAAP net loss reflected a $3.4 million

decrease in stock-based compensation expense, which is e
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015  Edico Genome ... and geneticists from Harvard and Stanford Universities showed ... whole genome sequence with 300x depth of coverage ... compared to 60 hours with standard software. ... a challenge, especially for individual research and clinical ...
(Date:4/27/2015)... NORTH BRUNSWICK, New Jersey , ... Pharmaceuticals, société de découverte médicamenteuse spécialisée ... d,agents antibiotiques destinés à soigner les ... annoncé aujourd,hui la présentation de données ... clinique majeur, le TXA709, dans la ...
(Date:4/27/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... on clinical study data involving ADXS31-164 (AT-014) that ... the American Association for Cancer Research (AACR) Annual ... Lm -LLO immunotherapy developed by Advaxis, Inc. ...
(Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
Breaking Biology Technology:Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28
... Both recombinant human , ... vitro to cleave long dsRNA, producing siRNA cocktails that are , ... (1-6). Dicer is an , ... enzyme responsible for cleavage of long dsRNAs to siRNA in the , ...
... Gene Specific siRNA Controls , ... research or you are an siRNA expert, ... the Silencer gene specific siRNA , ... contains 50 g of ready-to-use chemically synthesized and gel , ...
... siRNA designs now available , ... , ... highly effective siRNAs , High quality custom siRNA synthesis from The RNA Company ... choice of synthesis options , Premium ...
Cached Biology Technology:Dicer vs. RNase III for Preparation of siRNA Cocktails 2Dicer vs. RNase III for Preparation of siRNA Cocktails 3Control Your siRNA Research 2Control Your siRNA Research 3Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 2Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 3Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 4Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 5Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 6
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Clough has developed a novel method for eavesdropping ... bursts. The doctoral student at Rensselaer Polytechnic Institute ... waves to boost the distance from which researchers ... hidden explosives, chemicals, and other dangerous materials. ...
... Ever get a flu shot and still get the flu? If ... come thanks to a new discovery by researchers who found that ... ability of flu vaccines to ward off this deadly virus. A ... Journal of Leukocyte Biology ( http://www.jleukbio.org ) suggests that ...
... why primates differ from other mammals, and humans differ from ... genome that were once considered "junk." A new study ... Medicine finds that when a particular type of repetitive DNA ... genes, they can alter the rate at which proteins are ...
Cached Biology News:Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 3Drug to fight tumors also fights the flu and possibly other viruses 2U. Iowa team investigates function of 'junk DNA' in human genes 2U. Iowa team investigates function of 'junk DNA' in human genes 3
... (10 min) assay can detect H2O2 or ... (ADHP). H2O2 oxidizes ADHP in a 1:1 ... (excitation at 530-571 nm, emission at 590-600 ... in a one-step, homogeneous, no wash assay ...
... Description: ,Kit containing Dermal Fibroblasts ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ... ,Source: Dermis, mouse/BalbC, embryonic day 18.5 ...
... ABsolute QRT-PCR Mixes are formulated for ... primers and SYBR Green. One-step QRT-PCR mixes ... analysing RNA. The pipetting steps are minimised, ... automation possible. ,The 2x ABsolute QRT-PCR Mix ...
... for protein pull-down experiments to ... proteins. An order of Sphingobeads ... beads with 10 nmol of ... of the alkyl chain; enough ...
Biology Products: